细胞代谢与皮肤恶性黑素瘤转移的研究进展

doi:10.35541/cjd.20210023

Abstract

Abstract: 【Abstract】 In recent years, more and more attention has been paid to the role of metabolism in its invasion and metastasis of cutaneous malignant melanoma （CMM）. The plasticity of metabolism and transformation of the metabolic pattern can provide sufficient energy for the metastasis of CMM, and increase its invasiveness and adaptability to different environments. Besides, the interaction between CMM metabolism and tumor microenvironment also plays an important role in the progression of CMM. This review summarizes the latest progress in cell metabolism in the invasion and metastasis of CMM, and its interaction with tumor microenvironment, in order to provide new ideas for the research on mechanisms of CMM metastasis, as well as clinical targeted therapy and immunotherapy.

Key words: Nevi and melanomas, Metabolic networks and pathways, Tumor microenvironment, Neoplasm metastasis

Dong Dong, Liu Tianyi. Cell metabolism and metastasis of cutaneous malignant melanoma[J]. Chinese Journal of Dermatology, 2023, 56(9): 878-881.doi:10.35541/cjd.20210023

References ［39］

［1］	Zhang X, Cai L, Zhao S, et al. CX⁃F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy［J］. Biochem Pharmacol, 2019,168:14⁃25. doi: 10.1016/j.bcp.2019.06.014.
［2］	Parmenter TJ, Kleinschmidt M, Kinross KM, et al. Response of BRAF⁃mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis［J］. Cancer Discov, 2014,4（4）:423⁃433. doi: 10.1158/2159⁃8290.CD⁃13⁃0440.
［3］	高天文, 郭伟楠. 中国黑素瘤研究进展与新治疗策略［J］. 中华皮肤科杂志, 2021,54（1）:27⁃32. doi: 10.35541/cjd.20200560.
［4］	Khan A, Valli E, Lam H, et al. Targeting metabolic activity in high⁃risk neuroblastoma through Monocarboxylate Transporter 1 （MCT1） inhibition［J］. Oncogene, 2020,39（17）:3555⁃3570. doi: 10.1038/s41388⁃020⁃1235⁃2.
［5］	Kamenisch Y, Baban T, Schuller W, et al. UVA⁃irradiation induces melanoma invasion via the enhanced Warburg effect［J］. J Invest Dermatol, 2016,136（9）:1866⁃1875. doi: 10.1016/j.jid.2016.02.815.
［6］	Ubellacker JM, Tasdogan A, Ramesh V, et al. Lymph protects metastasizing melanoma cells from ferroptosis［J］. Nature, 2020,585（7823）:113⁃118. doi: 10.1038/s41586⁃020⁃2623⁃z.
［7］	Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment［J］. Semin Cancer Biol, 2019,59:236⁃250. doi: 10.1016/j.semcancer.2019.08.002.
［8］	Feichtinger RG, Lang R, Geilberger R, et al. Melanoma tumors exhibit a variable but distinct metabolic signature［J］. Exp Dermatol, 2018,27（2）:204⁃207. doi: 10.1111/exd.13465.
［9］	Scott DA, Richardson AD, Filipp FV, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect［J］. J Biol Chem, 2011,286（49）:42626⁃42634. doi: 10.1074/jbc.M111.282046.
［10］	Luís R, Brito C, Pojo M. Melanoma metabolism: cell survival and resistance to therapy［J］. Adv Exp Med Biol, 2020,1219:203⁃223. doi: 10.1007/978⁃3⁃030⁃34025⁃4_11.
［11］	Haq R, Shoag J, Andreu⁃Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF［J］. Cancer Cell, 2013,23（3）:302⁃315. doi: 10.1016/j.ccr.2013.02.003.
［12］	Sensi M, Nicolini G, Petti C, et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single⁃cell level in the same human melanoma［J］. Oncogene, 2006,25（24）:3357⁃3364. doi: 10.1038/sj.onc.1209379.
［13］	Chae YC, Vaira V, Caino MC, et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming［J］. Cancer Cell, 2016,30（2）:257⁃272. doi: 10.1016/j.ccell.2016.07.004.
［14］	Neagu M. Metabolic traits in cutaneous melanoma［J］. Front Oncol, 2020,10:851. doi: 10.3389/fonc.2020.00851.
［15］	Li Z, Liu J, Que L, et al. The immunoregulatory protein B7⁃H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway［J］. J Cancer, 2019,10（23）:5770⁃5784. doi: 10.7150/jca.29838.
［16］	Dang CV, Le A, Gao P. MYC⁃induced cancer cell energy metabolism and therapeutic opportunities［J］. Clin Cancer Res, 2009,15（21）:6479⁃6483. doi: 10.1158/1078⁃0432.CCR⁃09⁃0889.
［17］	Zeller KI, Jegga AG, Aronow BJ, et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets［J］. Genome Biol, 2003,4（10）:R69. doi: 10.1186/gb⁃2003⁃4⁃10⁃r69.
［18］	Ruby KN, Liu CL, Li Z, et al. Diagnostic and prognostic value of glucose transporters in melanocytic lesions［J］. Melanoma Res, 2019,29（6）:603⁃611. doi: 10.1097/CMR.0000000000000626.
［19］	Koch A, Ebert EV, Seitz T, et al. Characterization of glycolysis⁃related gene expression in malignant melanoma［J］. Pathol Res Pract, 2020,216（1）:152752. doi: 10.1016/j.prp.2019.152752.
［20］	Koch A, Lang SA, Wild PJ, et al. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells［J］. Oncotarget, 2015,6（32）:32748⁃32760. doi: 10.18632/oncotarget. 4977.
［21］	Burián Z, Ladányi A, Barbai T, et al. Selective inhibition of HIF1α expression by ZnSO4 has antitumoral effects in human melanoma［J］. Pathol Oncol Res, 2020,26（2）:673⁃679. doi: 10.1007/s12253⁃018⁃00573⁃1.
［22］	Corazao⁃Rozas P, Guerreschi P, Jendoubi M, et al. Mitochondrial oxidative stress is the Achille′s heel of melanoma cells resistant to Braf⁃mutant inhibitor［J］. Oncotarget, 2013,4（11）:1986⁃1998. doi: 10.18632/oncotarget.1420.
［23］	Wang L, Leite de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug⁃resistant melanoma with therapeutic potential［J］. Cell, 2018,173（6）:1413⁃1425.e14. doi: 10.1016/j.cell.2018.04.012.
［24］	Avagliano A, Fiume G, Pelagalli A, et al. Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment［J］. Front Oncol, 2020,10:722. doi: 10.3389/fonc.2020.00722.
［25］	Vashisht Gopal YN, Gammon S, Prasad R, et al. A novel mitochondrial inhibitor blocks MAPK Pathway and overcomes MAPK inhibitor resistance in melanoma［J］. Clin Cancer Res, 2019,25（21）:6429⁃6442. doi: 10.1158/1078⁃0432.CCR⁃19⁃0836.
［26］	Bizzozero L, Cazzato D, Cervia D, et al. Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia⁃associated transcription factor signalling pathway［J］. Cell Death Differ, 2014,21（4）:507⁃520. doi: 10. 1038/cdd.2013.173.
［27］	Coazzoli M, Napoli A, Roux⁃Biejat P, et al. Acid sphingomyelinase downregulation enhances mitochondrial fusion and promotes oxidative metabolism in a mouse model of melanoma［J］. Cells, 2020,9（4）:848. doi: 10.3390/cells9040848.
［28］	Tasdogan A, Faubert B, Ramesh V, et al. Metabolic heterogeneity confers differences in melanoma metastatic potential［J］. Nature, 2020,577（7788）:115⁃120. doi: 10.1038/s41586⁃019⁃1847⁃2.
［29］	Kfoury A, Armaro M, Collodet C, et al. AMPK promotes survival of c⁃Myc⁃positive melanoma cells by suppressing oxidative stress［J］. EMBO J, 2018,37（5）:e97673. doi: 10.15252/embj.201797673.
［30］	Lee CK, Jeong SH, Jang C, et al. Tumor metastasis to lymph nodes requires YAP⁃dependent metabolic adaptation［J］. Science, 2019,363（6427）:644⁃649. doi: 10.1126/science.aav0173.
［31］	Magtanong L, Ko PJ, To M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis⁃resistant cell state［J］. Cell Chem Biol, 2019,26（3）:420⁃432.e9. doi: 10.1016/j.chembiol. 2018.11.016.
［32］	Raica M, Jitariu AA, Cimpean AM. Lymphangiogenesis and anti⁃lymphangiogenesis in cutaneous melanoma［J］. Anticancer Res, 2016,36（9）:4427⁃4435. doi: 10.21873/anticanres.10986.
［33］	Garmy⁃Susini B, Avraamides CJ, Desgrosellier JS, et al. PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes［J］. Proc Natl Acad Sci U S A, 2013,110（22）:9042⁃9047. doi: 10.1073/pnas.1219603110.
［34］	Garmy⁃Susini B, Avraamides CJ, Schmid MC, et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis［J］. Cancer Res, 2010,70（8）:3042⁃3051. doi: 10.1158/0008⁃5472.CAN⁃09⁃3761.
［35］	Cortez A, Josefsson A, McCarty G, et al. Evaluation of ［（225）Ac］Ac⁃DOTA⁃anti⁃VLA⁃4 for targeted alpha therapy of metastatic melanoma［J］. Nucl Med Biol, 2020,88⁃89:62⁃72. doi: 10.1016/j.nucmedbio.2020.07.006.
［36］	Baumann F, Leukel P, Doerfelt A, et al. Lactate promotes glioma migration by TGF⁃beta2⁃dependent regulation of matrix metalloproteinase⁃2［J］. Neuro Oncol, 2009,11（4）:368⁃380. doi: 10.1215/15228517⁃2008⁃106.
［37］	Jacobs SR, Herman CE, Maciver NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28⁃mediated Akt⁃dependent and independent pathways［J］. J Immunol, 2008,180（7）:4476⁃4486. doi: 10.4049/jimmunol.180.7.4476.
［38］	Najjar YG, Menk AV, Sander C, et al. Tumor cell oxidative metabolism as a barrier to PD⁃1 blockade immunotherapy in melanoma［J］. JCI Insight, 2019,4（5）:e124989. doi: 10.1172/jci.insight.124989.
［39］	Kim SH, Roszik J, Grimm EA, et al. Impact of l⁃arginine metabolism on immune response and anticancer immunotherapy［J］. Front Oncol, 2018,8:67. doi: 10.3389/fonc.2018.00067.

[1]	Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.
[2]	Wang Yuanli, Liu Ling, Sun Zhongbin, Li Kai. Analysis of 141 cases clinically misdiagnosed as melanoma [J]. Chinese Journal of Dermatology, 2023, 56(3): 244-246.
[3]	Li Fang, Wang Xiaoqing, Liu Mengxi, Jiang Jiayi, Huang Shudai, Wang Daguang. Research advances in recurrent melanocytic nevus [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220431-e20220431.
[4]	Li Tingting, Kang Xiaojing. Gut microbiota and immune checkpoint inhibitor treatment of melanoma [J]. Chinese Journal of Dermatology, 2023, 56(2): 177-180.
[5]	Gao Ni, Liu Yu, Wang Lei, Liu Ling, Gao Tianwen, Li Kai . Clinical and histopathological analysis of five cases of solitary dermal melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 408-410.
[6]	He Suling, Tian Xin, Liang Jingyao, Shao Lei, Li Junlong, Huang Qiongxiao, Liu Yumei, Wang Jianqin. Skin microecology in patients with severe atopic dermatitis at acute and remission phases [J]. Chinese Journal of Dermatology, 2022, 55(4): 329-336.
[7]	Li Tingting, Guan Mengmeng, Zhao Juan, Kang Xiaojing. Application of single-cell RNA sequencing in melanoma research [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210191-e20210191.
[8]	Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158.
[9]	Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784.
[10]	Wang Daguang, Jiang Jiayi. Considerations in the diagnosis and treatment of several nail diseases [J]. Chinese Journal of Dermatology, 2021, 54(8): 733-737.
[11]	Wang Yanqing, Guo Ying. Pathological features and diagnosis of Spitz nevus [J]. Chinese Journal of Dermatology, 2021, 54(4): 308-312.
[12]	Zhu Mengyan, Li Zhao, Wang Jiaqi, Ma Yangyang, Zhang Xiaoyan, Wang Ping. Mechanisms regulating melanoma by the ubiquitin-conjugating enzyme E2S: a bioinformatics analysis [J]. Chinese Journal of Dermatology, 2021, 54(4): 300-307.
[13]	Sha Shanshan, Li Jun, Tao Juan. Melanoma immunotherapy: difficulties and strategies [J]. Chinese Journal of Dermatology, 2021, 54(4): 313-317.
[14]	Zhang Qian, Liu Yu, Wang Lei, Liu Ling, Gao Tianwen, Li Kai. Clinical and histopathological analysis of three cases of nevoid melanoma [J]. Chinese Journal of Dermatology, 2021, 54(11): 990-993.
[15]	Yan Dong, Guo Yanyang, Zhang Yuwei, Hai Luming, Gao Tianwen, Zhu Guannan. Dermoscopic features of 266 cases of melanonychia [J]. Chinese Journal of Dermatology, 2021, 54(11): 993-997.

Cell metabolism and metastasis of cutaneous malignant melanoma

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［39］

Related Articles 15

Metrics

Comments

Recommended 10